|
|
|
|
|
|
Sponsored by: |
Sheba Medical Center |
Information provided by: | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00552825 |
The aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment) and up to 3 years follow-up (study period).
Condition |
Acute Lymphoblastic Leukemia Acute Myeloblastic Leukemia Solid Tumors, Hodgkin's Disease Non-Malignant |
MedlinePlus related topics: | Cancer Hodgkin's Disease Leukemia, Childhood |
Study Type: | Observational |
Study Design: | Cohort, Retrospective |
Official Title: | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years |
Enrollment: | 35 |
Study Start Date: | October 2005 |
Study Completion Date: | October 2006 |
Groups/Cohorts |
1
all were in a single group
|
Pulmonary function tests (PFTs) are a part of the routine follow-up of patients receiving anti-cancer treatment. Treatment is frequently associated with diverse pulmonary damage which may become functionally and clinically evident many years later. PFTs may help to quantify the damage in the lungs; help to evaluate the point at which lung function deviates from normal to allow early intervention before irreversible lung damage occurs and thereby to reduce morbidity and mortality.
Reliable PFTs in the preschool age have traditionally been difficult to perform, but recent publications have demonstrated that the majority of preschool children can produce reproducible forced expiratory flow volume (FEVC) curves with proper coaching techniques. This recent development may enable studying the long term effect (years) of treatment on lung function in young children suffering from hemato-oncologic diseases.
Ages Eligible for Study: | 3 Years to 7 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
All pediatric patients (age 3-7 years) with hemato-onclogic diseases that were treated at the Hemato-Oncology Department, and were sent to the pediatric pulmonary unit at the Safra children's hospital, Sheba medical center, Ramat-Gan, Israel, to perform lung function tests, as a part of a 3-year follow-up study.
Inclusion Criteria:
Israel, Ramat Gan | |||||
Sheba Medical CenterPediatric pulmonary unit, Pulmonary function laboratory | |||||
Ramat-Gan, Ramat Gan, Israel, 52621 |
Sheba Medical Center |
Principal Investigator: | Ori Efrati, MD | Sheba Medical Center |
Study ID Numbers: | SHEBA-05-3889-OE-CTIL, Observational |
First Received: | November 1, 2007 |
Last Updated: | November 1, 2007 |
ClinicalTrials.gov Identifier: | NCT00552825 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
|
|
|